[go: up one dir, main page]

IL90381A0 - Expression of retrovirus gag protein in eukaryotic cells - Google Patents

Expression of retrovirus gag protein in eukaryotic cells

Info

Publication number
IL90381A0
IL90381A0 IL90381A IL9038189A IL90381A0 IL 90381 A0 IL90381 A0 IL 90381A0 IL 90381 A IL90381 A IL 90381A IL 9038189 A IL9038189 A IL 9038189A IL 90381 A0 IL90381 A0 IL 90381A0
Authority
IL
Israel
Prior art keywords
expression
eukaryotic cells
gag protein
retrovirus gag
retrovirus
Prior art date
Application number
IL90381A
Original Assignee
Smithkline Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Biolog filed Critical Smithkline Biolog
Publication of IL90381A0 publication Critical patent/IL90381A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
IL90381A 1988-06-03 1989-05-23 Expression of retrovirus gag protein in eukaryotic cells IL90381A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20227188A 1988-06-03 1988-06-03

Publications (1)

Publication Number Publication Date
IL90381A0 true IL90381A0 (en) 1989-12-15

Family

ID=22749175

Family Applications (1)

Application Number Title Priority Date Filing Date
IL90381A IL90381A0 (en) 1988-06-03 1989-05-23 Expression of retrovirus gag protein in eukaryotic cells

Country Status (8)

Country Link
EP (1) EP0345242A3 (en)
AP (1) AP129A (en)
AU (2) AU627465B2 (en)
IL (1) IL90381A0 (en)
NZ (1) NZ229297A (en)
PT (1) PT90731A (en)
WO (1) WO1991000904A1 (en)
ZA (1) ZA894137B (en)

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003794C (en) * 1988-12-01 2000-02-08 Hanne R. Johansen Expression of hiv proteins in drosophila cells
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
JP4383530B2 (en) 1996-04-05 2009-12-16 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド Alphavirus vectors with reduced inhibition of cellular macromolecular synthesis
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
AU743616B2 (en) * 1997-02-07 2002-01-31 Merck & Co., Inc. Synthetic HIV gag genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
WO1999024578A2 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
WO1999033869A2 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
CN1224708C (en) 1998-01-14 2005-10-26 启龙股份公司 Neisseria meningitidis antigen
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP2003201A3 (en) 1998-03-18 2008-12-31 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
EP2261350A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
DK2272859T3 (en) 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
TR200102500T2 (en) 1998-12-08 2002-03-21 Corixa Corporation Bracelets to treat Chlamydia infection.
WO2000036118A2 (en) 1998-12-16 2000-06-22 Chiron Corporation HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
EA005140B1 (en) 1999-04-02 2004-12-30 Корикса Корпорейшн Compounds and methods for therapy and diagnosis of lung cancer
US8143386B2 (en) 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
WO2001024820A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
PT2275552E (en) 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Neisserial antigenic peptides
EP2163626A1 (en) 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Human FGF-21 gene and gene expression products
BR0107679A (en) 2000-01-17 2004-07-06 Chiron Spa Outer membrane vesicle (omv) vaccine comprising neisseria meningitidis serum group b outer membrane proteins
EP1854476A3 (en) 2000-02-09 2008-05-07 Bas Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
KR100848973B1 (en) 2000-02-23 2008-07-30 글락소스미스클라인 바이오로지칼즈 에스.에이. Tumour-specific animal proteins
AU2001239488B2 (en) 2000-02-28 2006-01-19 Glaxosmithkline Biologicals S.A. Heterologous expression of neisserial proteins
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1261638A2 (en) 2000-03-08 2002-12-04 Chiron Corporation Human fgf-23 gene and gene expression products
ES2303525T3 (en) 2000-04-21 2008-08-16 Corixa Corporation COMPOUNDS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF INFECTION BY CHLAMYDIA.
ES2305086T3 (en) 2000-05-19 2008-11-01 Corixa Corporation PROFILACTIC AND THERAPEUTIC TREATMENT OF ALLERGIC, AUTOIMMUNE AND INFECTIOUS DISEASES WITH COMPOUNDS BASED ON MONOSACARIDS.
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2001096523A2 (en) 2000-06-15 2001-12-20 Chiron Corporation Polynucleotides related to colon cancer
EP2133100B1 (en) 2000-06-20 2011-10-05 Corixa Corporation MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
EP1319069B1 (en) 2000-06-28 2008-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
ATE439372T1 (en) 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic NUCLEIC ACIDS AND PROTEINS OF GROUP A AND B STREPTOCOCICS
AU2002227365A1 (en) 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
AU2002359446B2 (en) 2001-11-09 2008-12-04 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
AU2002366592B2 (en) 2001-12-12 2008-01-10 Novartis Vaccines And Diagnostics S.R.L. Immunisation against Chlamydia trachomatis
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
SG148035A1 (en) 2002-01-08 2008-12-31 Novartis Vaccines & Diagnostic Gene products differentially expressed in cancerous breast cells and their methods of use
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2479118A1 (en) 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
WO2003080808A2 (en) 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
ATE545651T1 (en) 2002-06-13 2012-03-15 Novartis Vaccines & Diagnostic VECTORS FOR EXPRESSING HML-2 POLYPEPTIDES
EP2865386B1 (en) 2002-07-18 2017-07-05 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
AU2003285864C1 (en) 2002-10-08 2010-07-01 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
KR101410692B1 (en) 2002-12-24 2014-06-24 리나트 뉴로사이언스 코프. Anti-ngf antibodies and methods using same
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
RU2389732C2 (en) 2003-01-06 2010-05-20 Корикса Корпорейшн Certain aminoalkyl glucosaminide phospahte derivatives and use thereof
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
AU2004213452A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic GPCR targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EA010159B1 (en) 2003-02-19 2008-06-30 Ринат Ньюросайенс Корп. METHODS OF TREATMENT OF PATIENTS BY INTRODUCING ANTAGONIST OF NERVES GROWTH FACTOR AND NONSTEROID ANTI-INFLAMMATORY MEANS AND CONTAINING THEIR COMPOSITIONS
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US8052966B2 (en) 2003-04-21 2011-11-08 University Of Southern California Methods and compositions for treating metastatic cancer
US7812116B2 (en) 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
EP1700121A4 (en) 2003-12-23 2008-09-03 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
KR101222281B1 (en) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 Novel galectin 9 modification protein and use thereof
SI1732949T1 (en) 2004-04-07 2010-05-31 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
DK2199801T3 (en) 2004-07-14 2013-08-05 Univ California Biomarkers for early detection of ovarian cancer
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
KR20070040824A (en) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 Antibodies directed against amyloid-beta peptides and methods of use thereof
WO2006020684A2 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
JP2008513406A (en) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
AU2006216844B2 (en) 2005-02-18 2012-11-08 Novartis Vaccines And Diagnostics S.R.L. Immunogens from uropathogenic escherichia coli
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
KR20070121814A (en) 2005-03-31 2007-12-27 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccines against Chlamydia Infection
JP2008535494A (en) 2005-04-07 2008-09-04 サグレシュ ディスカバリー， インコーポレイテッド Cancer-related gene (PRLR)
EP2062591A1 (en) 2005-04-07 2009-05-27 Novartis Vaccines and Diagnostics, Inc. CACNA1E in cancer diagnosis detection and treatment
ES2524572T3 (en) 2005-04-29 2014-12-10 Glaxosmithkline Biologicals S.A. Novel procedure for prevention or treatment of infection with M. tuberculosis
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
RU2486204C2 (en) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Cd26 antibodies and methods of using them
CN101309704B (en) 2005-11-14 2012-10-10 礼纳特神经系统科学公司 Antagonist antibodies against calcitonin gene-related peptide and methods of use thereof
JP2009522372A (en) 2006-01-09 2009-06-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Combination immunostimulant of TNFRSF, TLR, NLR, RHR, purine receptor, and cytokine receptor agonist for vaccine and tumor immunotherapy
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
US7935342B2 (en) 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
KR101510753B1 (en) 2006-06-07 2015-04-10 바이오얼라이언스 씨.브이. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
JP2010500399A (en) 2006-08-16 2010-01-07 ノバルティス アーゲー Immunogen from Urinary Pathogenic Escherichia coli
WO2008116116A2 (en) 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN106977601A (en) 2007-12-17 2017-07-25 辉瑞有限公司 The treatment of interstitial cystitis
KR101672271B1 (en) 2007-12-18 2016-11-03 바이오얼라이언스 씨.브이. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
US10000568B2 (en) 2008-04-10 2018-06-19 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
US20110287026A1 (en) 2008-09-23 2011-11-24 President And Fellows Of Harvard College Sirt4 and uses thereof
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
JP2012519482A (en) 2009-03-06 2012-08-30 ノバルティス アーゲー Chlamydia antigen
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
MX2011010735A (en) 2009-04-14 2012-01-25 Novartis Ag Compositions for immunising against staphylococcus aerus.
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
US8871214B2 (en) 2009-07-16 2014-10-28 Novartis Ag Detoxified Escherichia coli immunogens
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
AU2011207348A1 (en) 2010-01-21 2012-08-02 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
AR080291A1 (en) 2010-02-24 2012-03-28 Rinat Neuroscience Corp ANTI-BODIES ANTAGONISTS ANTI RECEIVER OF IL-7 AND PROCEDURES
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
KR20150002894A (en) 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
US9198975B2 (en) 2010-12-01 2015-12-01 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
WO2012154994A2 (en) 2011-05-10 2012-11-15 The Regents Of The University Of Californa A novel adenovirus isolated from titi monkeys
EP2723365A1 (en) 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
WO2013033260A1 (en) 2011-08-29 2013-03-07 The Regents Of The University Of California Use of hdl-related molecules to treat and prevent proinflammatory conditions
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
CA2854720C (en) 2011-11-11 2018-12-18 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
RU2014123030A (en) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. ANTAGONISTIC ANTIBODIES AGAINST THE HUMAN GROWTH HORMONE RECEPTOR AND WAYS OF THEIR APPLICATION
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
RU2015115956A (en) 2012-11-09 2017-01-10 Пфайзер Инк. ANTIBODIES SPECIFIC TO THE THROMBOCYTE B GROWTH FACTOR, AND THEIR COMPOSITION AND APPLICATION
CA2902975C (en) 2013-03-14 2021-05-11 Epeius Biotechnologies Corporation Thymidine kinase diagnostic assay for gene therapy applications
US20160017055A1 (en) 2013-03-15 2016-01-21 Dyax Corp. Anti-plasma kallikrein antibodies
BR112015023500B1 (en) 2013-03-15 2021-01-12 The Regents Of The University Of California pharmaceutical composition
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
JP2016518126A (en) 2013-04-19 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Lone Star Virus
CA2911412A1 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
WO2014210546A1 (en) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
WO2015003003A1 (en) 2013-07-01 2015-01-08 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
PE20160671A1 (en) 2013-08-02 2016-07-09 Pfizer ANTI-CXCR4 ANTIBODIES AND ANTIBODY AND DRUG CONJUGATES
AU2014348676B2 (en) 2013-11-13 2020-06-18 Bristol-Myers Squibb Company Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
MX378344B (en) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING THEM.
KR102555955B1 (en) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 Compositions and methods for treatment of diabetic macular edema
AU2015249374A1 (en) 2014-04-24 2016-12-01 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
US10329556B2 (en) 2014-05-13 2019-06-25 Bioatla, Llc Conditionally active biological proteins
AU2015277194B2 (en) 2014-06-17 2020-10-22 The Research Foundation For The State University Of New York Ship inhibition to induce activation of natural killer cells
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7286267B2 (en) 2014-08-28 2023-06-05 バイオアトラ インコーポレイテッド Conditionally active chimeric antigen receptor for modified T cells
KR20170044115A (en) 2014-09-03 2017-04-24 바이오아트라, 엘엘씨 Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
JP2017527310A (en) 2014-09-09 2017-09-21 ユーナム・セラピューティクスＵｎｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Chimeric receptors and their use in immunotherapy
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
JP6941561B2 (en) 2014-10-09 2021-09-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Multiple variable IL-2 dose regimens for treating immune disorders
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-PD-1 antibodies and methods of using same
EP4670785A2 (en) 2015-01-02 2025-12-31 Takeda Pharmaceutical Company Limited BISPECIFIC ANTIBODIES AGAINST PLASMA CALICREIN AND FACTOR XII
US10948492B2 (en) 2015-03-06 2021-03-16 Dana-Farber Cancer Institute, Inc. PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
PL3283106T3 (en) 2015-04-13 2022-05-02 Pfizer Inc. Therapeutic antibodies and their uses
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
AU2016297018B9 (en) 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
KR20230074843A (en) 2015-08-19 2023-05-31 화이자 인코포레이티드 Tissue factor pathway inhibitor antibodies and uses thereof
JP7107836B2 (en) 2015-09-15 2022-07-27 スカラー ロック インコーポレイテッド Anti-pro/latent myostatin antibodies and uses thereof
CN108431214B (en) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) Human rotavirus G9P[6] strain and use as vaccine
CN108290939B (en) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 Compositions and methods for inhibiting lineage specific antigens
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
TW201722989A (en) 2015-10-23 2017-07-01 輝瑞大藥廠 Anti-IL-2 antibody, composition and use thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CA3002676A1 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
CN106699889A (en) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 PD-1 resisting antibody and treatment application thereof
CN108712911A (en) 2015-12-30 2018-10-26 科达制药股份有限公司 Antibody and its conjugate
ES2904593T3 (en) 2016-01-21 2022-04-05 Pfizer Monospecific and bispecific antibodies to epidermal growth factor receptor variant III and CD3 and their uses
CN110753755B (en) 2016-03-21 2023-12-29 丹娜法伯癌症研究院 T cell depletion state specific gene expression regulator and application thereof
CA3029582A1 (en) 2016-07-01 2018-01-04 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
CA3034643A1 (en) 2016-09-20 2018-03-29 Ellen Weisberg Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
WO2018148246A1 (en) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
CA3054885A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
EP3596206A1 (en) 2017-03-16 2020-01-22 Pfizer Inc Tyrosine prototrophy
US11584790B2 (en) 2017-04-14 2023-02-21 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
EP3615570A4 (en) 2017-04-25 2021-02-24 LBL Biotechnology Inc. Use of il-20 antagonists for treating eye diseases
TWI790120B (en) 2017-06-02 2023-01-11 美商輝瑞大藥廠 Antibodies specific for flt3 and their uses
AU2018284077B2 (en) 2017-06-13 2021-09-23 Bostongene Corporation Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
CA3069179A1 (en) 2017-07-13 2019-01-17 Massachusetts Institute Of Technology Targeting the hdac2-sp3 complex to enhance synaptic function
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra Anti-nucleolin antibody
EP4088783A1 (en) 2017-08-01 2022-11-16 Ab Studio Inc. Bispecific antibodies and uses thereof
US11970707B2 (en) 2017-09-18 2024-04-30 Children's Hospital Medical Center Strong insulator and uses thereof in gene delivery
KR102543719B1 (en) 2017-09-21 2023-06-16 유큐(베이징) 바이오파마 코., 엘티디 Anti-CTLA4 Antibodies and Uses Thereof
AU2018344859A1 (en) 2017-10-04 2020-04-30 Hesperix SA Articles and methods directed to personalized therapy of cancer
EP4597112A2 (en) 2017-10-27 2025-08-06 New York University Anti-galectin-9 antibodies and uses thereof
AU2017440393B2 (en) 2017-11-24 2025-02-20 Eucure (Beijing) Biopharma Co., Ltd Anti-OX40 antibodies and uses thereof
PE20252242A1 (en) 2018-02-01 2025-09-15 Pfizer CHIMERIC ANTIGEN RECEPTORS TARGETED AT CD70
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
EP3755342A4 (en) 2018-02-21 2021-11-24 The University Of Montana DIARYL TREHALOSE COMPOUNDS AND THEIR USES
IL276675B2 (en) 2018-02-23 2023-10-01 Eucure Beijing Biopharma Co Ltd Anti-pd-1 antibodies and uses thereof
US20210032334A1 (en) 2018-02-28 2021-02-04 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
RU2020128440A (en) 2018-02-28 2022-03-28 Пфайзер Инк. IL-15 OPTIONS AND THEIR APPLICATIONS
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
MX2020010094A (en) 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof.
SG11202010934SA (en) 2018-05-23 2020-12-30 Pfizer Antibodies specific for gucy2c and uses thereof
PT3797121T (en) 2018-05-23 2024-08-23 Pfizer CD3-SPECIFIC ANTIBODIES AND THEIR USE
EP3817763B1 (en) 2018-07-03 2025-09-03 SOTIO Biotech Inc. Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
SG11202100510PA (en) 2018-07-20 2021-02-25 Eucure Beijing Biopharma Co Ltd Anti-cd40 antibodies and uses thereof
WO2020037066A1 (en) 2018-08-14 2020-02-20 Unum Therapeutics Inc. Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2020052581A1 (en) 2018-09-12 2020-03-19 Eucure (Beijing) Biopharma Co., Ltd Anti-tnfrsf9 antibodies and uses thereof
JP7603580B2 (en) 2018-10-15 2024-12-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド Antibodies to granulocyte-macrophage colony-stimulating factor and uses thereof
CA3116564A1 (en) 2018-11-19 2020-05-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-pd-1 antibodies and uses thereof
TWI851634B (en) 2018-12-21 2024-08-11 大陸商沐特圖公司 Antibodies specific to muc18
JP7549584B2 (en) 2019-01-23 2024-09-11 ニューヨーク・ユニバーシティ Antibody specific for the delta 1 chain of the T cell receptor
WO2020159918A2 (en) 2019-01-28 2020-08-06 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
WO2020169022A1 (en) 2019-02-18 2020-08-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animals with humanized immunoglobulin locus
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
AU2020278777A1 (en) 2019-05-23 2021-12-16 The University Of Montana Vaccine adjuvants based on TLR receptor ligands
EP3994696B1 (en) 2019-07-03 2025-05-14 BostonGene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
EP4093513A4 (en) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
US20230181750A1 (en) 2020-05-06 2023-06-15 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
KR20230018439A (en) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 Genetically Modified Non-Human Animals with Common Light Chain Immunoglobulin Loci
EP4165071A4 (en) 2020-06-15 2024-07-17 Academia Sinica HUMANIZED ACE2-FC FUSION PROTEIN FOR THE TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION
WO2022013775A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
EP4189093A1 (en) 2020-07-30 2023-06-07 Pfizer Inc. Cells having gene duplications and uses thereof
WO2022086852A2 (en) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2022104104A2 (en) 2020-11-13 2022-05-19 Dana-Farber Cancer Institute, Inc. Personalized fusion cell vaccines
US12254961B2 (en) 2020-12-04 2025-03-18 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
US20220372580A1 (en) 2021-04-29 2022-11-24 Bostongene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
JP2024528139A (en) 2021-08-02 2024-07-26 ファイザー・インク Improved expression vectors and uses thereof
IL311712A (en) 2021-09-27 2024-05-01 Sotio Biotech Inc Chimeric polypeptide receptors combined with trans-metabolism compounds that divert glucose metabolites outside the glycolysis pathway and their medical uses
CN118488969A (en) 2021-11-16 2024-08-13 舒迪安生物技术公司 Treatment of patients with myxoid/round cell liposarcoma
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
CA3249858A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
US20250304911A1 (en) 2022-02-02 2025-10-02 Pfizer Inc. Cysteine prototrophy
CA3249166A1 (en) 2022-02-16 2023-08-24 The Johns Hopkins University Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2024015561A1 (en) 2022-07-15 2024-01-18 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025034542A1 (en) 2023-08-04 2025-02-13 Cornell University Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy
WO2025096811A1 (en) 2023-10-31 2025-05-08 Bostongene Corporation Machine learning technique for identifying ici responders and non-responders
US20250253011A1 (en) 2024-02-02 2025-08-07 Seven Bridges Genomics Inc. Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
WO2025202361A1 (en) 2024-03-27 2025-10-02 Adcendo Aps Anti-gpc1 antibodies and uses thereof
WO2025202359A1 (en) 2024-03-27 2025-10-02 Adcendo Aps Anti-gpc1 antibodies and uses thereof
WO2025223455A1 (en) 2024-04-24 2025-10-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ptk7/b7h3 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931799A (en) * 1982-08-16 1984-02-20 Science & Tech Agency Recombinant plasmid and preparation of transformed yeast and hepatitis virus b surface antigen using the same
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
NO870027L (en) * 1986-01-06 1987-07-07 Hoffmann La Roche EXPRESSION OF HTLV-III GAG GEN.
EP0301083A4 (en) * 1987-02-11 1990-09-26 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
IL90048A0 (en) * 1988-04-25 1989-12-15 Merck & Co Inc Recombinant gag precursor of hiv,its preparation and its use as aids vaccine

Also Published As

Publication number Publication date
AU4320689A (en) 1991-02-06
PT90731A (en) 1989-12-29
WO1991000904A1 (en) 1991-01-24
AU3725689A (en) 1991-01-03
AP8900126A0 (en) 1989-07-31
AU627465B2 (en) 1992-08-27
NZ229297A (en) 1992-01-29
EP0345242A3 (en) 1990-05-30
ZA894137B (en) 1990-06-27
EP0345242A2 (en) 1989-12-06
AP129A (en) 1991-04-17

Similar Documents

Publication Publication Date Title
IL90381A0 (en) Expression of retrovirus gag protein in eukaryotic cells
GB8817997D0 (en) Enzyme electrodes & improvements in manufacture thereof
IL91843A0 (en) Hiv proteins and peptides useful in the diagnosis,prophylaxis aids or therapy of aids
AU6399786A (en) Polypeptides used in the diagnosis and therapy of AIDS
IL89567A0 (en) Mutated hiv envelope protein
NZ224667A (en) Stable human cell lines expressing foreign gene under hiv ltr regulatory control
GB2190382B (en) "enhanced expression of human interleukin-2 or analogues in mammalian cells.
ZA886273B (en) Novel hiv proteins and peptides useful in the diagnosis,prophylaxis or therapy of aids
DK381287A (en) POLYPEPTIDES AND THEIR PREPARATION AND USE
IL83347A0 (en) Recombinant htlv-iii proteins and their use
AU8891691A (en) Human proteins having anticoagulant and anti-inflammatory activity
DK515386A (en) BENZOYLURINE INGREDIENTS AND THEIR PREPARATION AND USE
GB8629116D0 (en) Env/gag polypeptides
IE891750L (en) Expression of retrovirus gag protein in eukaryotic cells
ZA888701B (en) Expression of hiv proteins in e.coli and s. cerevisiae
AU8161287A (en) Improvements in or relating to antiallergy agents
PT79810A (en) Expression of human alpha-1-antitrysin in yeast
IL92470A (en) Expression of hiv proteins in drosophila cells
ZA883878B (en) Human immunodeficiency virus gag-encoded proteins
IE891349L (en) EXPRESSION OF THE HIV kDa GAG PROTEIN IN YEAST
IE893803L (en) Expression of hiv proteins in drosophila cells
IE883483L (en) Expression of hiv proteins
IL89993A0 (en) Expression of the hiv 24kda gag protein in methylotrophic yeasts
SU1592860A1 (en) Educational aid in strength of materials
IE883848L (en) Human b lympoblastoid cell